Theratechnologies Announces Agreement With AIDS Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
117
Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo™ and EGRIFTA®

MONTREAL, May 23, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH ) is pleased to announce that it has reached a pricing agreement with the AIDS Drug Assistance Program Crisis Task Force. The agreement opens access to Trogarzo™ (ibalizumab-uiyk) injection and EGRIFTA ® (tesamorelin for injection) to low income, underinsured and uninsured Americans in all 50 states and the territories.

Trogarzo™ represents a critical new treatment advance as the first HIV therapy with a new mechanism of action approved in 10 years and proven efficacy in difficult-to-treat patients with multi-drug resistant HIV-1.

EGRIFTA ® is a growth hormone-releasing factor analog and is the only FDA-approved treatment indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

“I am very proud of the agreement we concluded with ADAP. Both Trogarzo™ and EGRIFTA ® are uniquely indicated to address important unmet medical needs of people living with HIV. We want to ensure that no one is left behind and ultimately having both products on ADAP’s formularies will go a long way towards this goal,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

Formed in 2002, the Task Force negotiates reduced drug prices for all ADAPs. ADAPs provide HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states and the territories. Task Force membership is currently comprised of representatives from Arizona, California, Florida, Illinois, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia, and Washington state HIV/AIDS divisions.

About Trogarzo TM (ibalizumab-uiyk) injection TROGARZO is a CD4-directed post-attachment HIV-1 inhibitor.

Trogarzo™, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Before you receive Trogarzo™, tell your healthcare provider if you are pregnant or plan to become pregnant as it is not known if Trogarzo™ may harm your unborn baby or if you are breastfeeding or plan to breastfeed as it is not known if Trogarzo™ passes into breast milk.

Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements.

Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your health care provider right away if you start having new symptoms after starting your HIV-1 medicine.

The most common side effects of Trogarzo™ include diarrhea, dizziness, nausea and rash. These are not all the possible side effects of Trogarzo™. For more information, ask your healthcare provider or pharmacist. Full prescribing information available at www.trogarzo.com .

About EGRIFTA ® (tesamorelin for injection) EGRIFTA ® is currently approved in the United States, Canada and Mexico.

You should not take EGRIFTA ® if you

  • have or have ever had any problems with your pituitary gland.
  • have cancer or are receiving treatment for cancer.
  • are allergic to tesamorelin or any of the ingredients in EGRIFTA ® .
  • are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA ® and talk with your healthcare provider.
  • are less than 18 years of age.

The most common side effects of EGRIFTA ® include: joint pain, pain in legs and arms, swelling in your legs, muscle pain, tingling, numbness and pricking, nausea, vomiting.  Full prescribing information is available at www.egrifta.com .

About Theratechnologies Theratechnologies (TSX: TH ) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com .

FORWARD-LOOKING INFORMATION This press release contains statements that are considered forward-looking information (“FLI”) within the meaning of securities laws that are based on our management’s belief and assumptions and on information currently available to our management. The forward-looking statements contained in this press release include, but are not limited to, the availability of reimbursements of Trogarzo TM and EGRIFTA ® by ADAP to patients. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the availability of both Trogarzo TM and EGRIFTA ® , no restrictions on the reimbursement of both of those drugs and eligibility of patients to seek reimbursement from ADAP. These risks and uncertainties include, but are not limited to, the risk that Trogarzo TM and EGRIFTA ® are subject to recalls, termination of our agreement with ADAP and rejected demand for reimbursement of any of those drugs by ADAP.  We refer potential investors to the “Risk Factors” section of our Annual Information Form (AIF) dated February 6, 2018 for additional risks and uncertainties about Theratechnologies. The AIF is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Information: Denis Boucher Vice President, Communications and Corporate Affairs 514-336-7800 ext. 236 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Join Flywire Corporation Securities Class Action

Updated Category News Views 219

Investors Urged to Join Flywire Corporation Securities Class Action The recent developments surrounding Flywire Corporation (NASDAQ: FLYW) have captured the attention of investors, especially those who purchased securities during the specified period. The Rosen Law Firm, known for championing investor rights, is taking the lead in facilitating a securities fraud lawsuit...

Continue Reading
Unicycive Therapeutics Faces Investigation Over Stock Concerns

Updated Category News Views 231

Unicycive Therapeutics Under Investigation for Securities Fraud In recent developments, Pomerantz LLP has initiated an investigation into the possible fraudulent activities involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The inquiry focuses on whether the company and its executives may have violated securities laws, an issue that could have implications for many...

Continue Reading
Investors Urged to Act: Join Wolfspeed's Upcoming Class Action

Updated Category News Views 313

Overview of Wolfspeed's Class Action Wolfspeed, Inc. investors are encouraged to take action regarding their stakes in the company as a class action lawsuit surfaces. The Rosen Law Firm, a reputable entity specializing in investor rights, sets a significant deadline for participation in this case. It’s essential for anyone who purchased shares within the specified...

Continue Reading
Pacsun Champions Co-Creation at Music's Grandest Stage

Updated Category News Views 194

Pacsun Champions Co-Creation at Music's Grandest Stage Youth Retailer Debuts Co-Branded Merchandise and Artist Performances As Grammy Weekend celebrates the top talents in music, Pacsun embraces the opportunity to highlight the emerging artists and professionals shaping the future of music. Their approach emphasizes co-creation, access, and cultural participation, crucial...

Continue Reading
Vistra Corp Enhances Financial Stability with Credit Facility Boost

Updated Category News Views 134

Vistra Corp Strengthens Financial Flexibility In a strategic move to enhance its financial flexibility, Vistra Corp. (NYSE:VST), known for delivering electric services, has taken steps to amend its credit agreement. The changes not only extend the maturity date of its credit facility but also expand its borrowing capabilities. This adjustment, effective October 2, 2024,...

Continue Reading